Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial
<p><strong>Background</strong></p> <p>Irbesartan, a long acting selective angiotensin-1 receptor inhibitor, in Marfan syndrome might reduce aortic dilatation, which is associated with dissection and rupture. We aimed to determine the effects of irbesartan on the rate of...
| Autors principals: | , , , |
|---|---|
| Format: | Journal article |
| Idioma: | English |
| Publicat: |
Elsevier
2019
|